Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Dec 5, 2017Tools now available to help adolescents with epilepsy transition to the adult health care system underscoring Eisai's leadership and commitment to the epilepsy communityThe Child Neurology Foundation (CNF) and Eisai today announced the availability of original resources aimed at helping those living with epilepsy navigate and simplify the transition from their...
-
Nov 22, 2017Data of note includes post-hoc analysis identifying potential predictors of major response to treatment with perampanel
Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These data will be presented at the American Epilepsy...
-
Oct 30, 2017
Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting, highlighting data on innovative ways to screen for...
-
Jul 26, 2017- First antiepileptic drug (AED) to apply FDA's regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to patients sooner
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for FYCOMPA® (perampanel) CIII as monotherapy use...
-
Jul 17, 2017
Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International...